Previous research indicates that patients who received PD-1 inhibitors had a higher occurrence of grade 3 or higher irAEs (201) and were more susceptible to pneumonia and thyroiditis (202). This evidence concerns the gene PDCD1 and susceptibility to pneumonia measurement.